You are here: Industry Insights > cancer immunotherapies

News List

Gilead, oNKo-innate to develop NK cells-focused cancer immunotherapies pharmaceutical-business-review
April 26, 2020
Gilead Sciences and its subsidiary Kite have joined forces with oNKo-innate to discover and develop cancer immunotherapies focused on natural killer (NK) cells.
Fate Therapeutics Announces Cancer Immunotherapies Collaboration americanpharmaceuticalreview
April 09, 2020
Fate Therapeutics announced a global collaboration and option agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
AZ’s cancer drug fails again, Roche’s rival gets new use pharmaphorum
December 10, 2018
AstraZeneca’s immunotherapy Imfinzi has failed in another late stage study, while Roche’s rival Tecentriq combination has been approved in the sought-after first line lung cancer indication.
Edge Therapeutics & PDS Biotechnology to Merge contractpharma
November 27, 2018
Expected to create a combined company with a growing pipeline of next generation cancer immunotherapies
Edge Therapeutics & PDS Biotechnology to Merge contractpharma
November 27, 2018
Expected to create a combined company with a growing pipeline of next generation cancer immunotherapies
Novartis, Harvard team up for cancer immunotherapies biospectrumasia
March 26, 2018
Novartis will have worldwide rights, in target-limited applications, to bring the biomaterial-based cancer immunotherapies into clinical development and translate this approach to treat patients.
Genentech to present new data on personalized medicines and cancer immunotherapies cphi-online
May 15, 2017
New pivotal results for Perjeta and Alecensa demonstrating improvement over standards of care.
Pierre Fabre and H-Immune Announce Strategic Research Partnership to Develop Potentially Ground-Brea firstwordpharma
March 22, 2017
Pierre Fabre, the second largest privately held pharmaceutical company in France, and H-Immune SAS, an emerging biotechnology company focused on developing first in class immunotherapies for treatment of various cancers, today announced that they have ent
Amgen and Immatics enter strategic collaboration to develop novel bispecific cancer immunotherapies worldpharmanews
January 13, 2017
Amgen and Immatics Biotechnologies GmbH, a leading company in the field of cancer immunotherapy, have announced a research collaboration and exclusive license agreement to develop next-generation, T-cell engaging bispecific immunotherapies targeting multi